Search - tctmd.com

Displaying 21 - 40 of 40

Sort: Relevancy | Date

Presentation TCT 2019

Case Introduction: DAPT Dilemma After a Complex PCI in a High Bleeding Risk Patient

Presenter: Amit Vora

September 26, 2019

News Conference News TCT 2018

EXCEL Deep Dive: Repeat Revascularization, Medical Therapy, and Anemia All Impact Patient Prognosis

Michael O'Riordan

September 21, 2018

Presentation TCT 2018

TCT-111: Efficacy and Safety of Glycoprotein IIb/IIIa Inhibitors on Top of a Potent P2Y12 Inhibitor in STEMI: A Pre-Specified Sub-Analysis of the ATLANTIC Trial

Presenter: George D. Dangas, Germano Di Sciascio, Anne Tavenier

September 21, 2018

Presentation TCT 2017

Switching Between Oral P2Y12 Receptor Inhibitors: When and How?

Presenter: Dominick J. Angiolillo, Marco Valgimigli, Matthew J. Price

October 30, 2017

Presentation TCT 2017

Crushing and Chewing Oral P2Y12 Receptor Inhibitors: Pharmacodynamic and Clinical Impact

Presenter: Dominick J. Angiolillo, Marco Valgimigli, Fabiana Rollini

October 30, 2017

Presentation TCT 2017

Debate: Making the Case for Not Pretreating ACS patients With Oral P2Y12 Receptor Inhibitors!

Presenter: John A. Bittl, Freek W.A. Verheugt, Somjot S. Brar

October 30, 2017

Presentation TCT 2017

Debate: Making the Case for Pretreating ACS patients With Oral P2Y12 Receptor Inhibitors!

Presenter: John A. Bittl, Freek W.A. Verheugt, Dimitrios Alexopoulos

October 30, 2017

Presentation TCT 2017

Treatment of Coronary Bifurcations in the Contemporary Era of P2Y12 Inhibitors and "Biologically Active Stents"

Presenter: Davide Capodanno, David Hildick-Smith, Marco Zimarino

October 30, 2017

News Conference News TCT 2017

Help for Clinicians Whose Patients Need to Switch P2Y12 Inhibitors

Todd Neale

October 30, 2017

Presentation TCT 2016

Intravenous P2Y12 Receptor Inhibitors Transitioning to a Potent Oral Anti-platelet Agent if PCI Is Performed Is Optimal Treatment in NSTE-ACS

Presenter: Roxana Mehran, Ferdinando Varbella, Dominick J. Angiolillo

November 01, 2016

Presentation TCT 2016

TCT 6: Simultaneous Impact of Thrombotic and Bleeding Risks on Use of Novel P2Y12 Inhibitors in Contemporary PCI: Results From a Large Single-Center Registry

Presenter: Dimitrios Alexopoulos, Laurent Bonello, Usman Baber

October 31, 2016

Presentation TCT 2016

Transitioning Between Cangrelor and Oral P2Y12 Inhibitors: All the Permutations

Presenter: Deepak L. Bhatt, Christian W. Hamm, Paul A. Gurbel

October 30, 2016

Presentation TCT 2015

PAR-1 Antagonists and P2Y12 Inhibitors: What Are the Data and the Place of These Medications in the PAD Population (for Secondary Cardiovascular Prevention and PAD Itself)?

Presenter: Gary M. Ansel, Michael R. Jaff, Ori Ben-Yehuda

October 11, 2015

News Conference News TCT 2015

Experts Debate Optimal Pharmacologic Approach for STEMI Patients

October 11, 2015

News Conference News TCT 2014

Skeptic’s Corner: Experts Debate Aspirin Use in Patients with AF Receiving DES

Todd Neale

September 13, 2014

News Conference News TCT 2013

Studies Find Differing Benefits of Platelet, Genotype Testing

October 31, 2013

News Conference News TCT 2013

EUROMAX: Prehospital Bivalirudin Reduces Bleeding in STEMI

October 30, 2013

News Conference News TCT 2012

Presentations Examine Multiple Facets of Antiplatelet Agents

October 24, 2012

Presentation TCT 2012

P2Y12 Inhibitors: Specific Agents for Specific Patient Cohorts? (STEMI, Diabetes, CKD, Prior Stroke, Etc.)

Presenter: Dirk Sibbing

October 22, 2012

Presentation TCT 2012

P2Y12 Inhibitors: Could Platelet Reactivity to Balance Between Bleeding and Ischemic Events

Presenter: Laurent Bonello

October 22, 2012

Advertisement

Case Introduction: DAPT Dilemma After a Complex PCI in a High Bleeding Risk Patient

EXCEL Deep Dive: Repeat Revascularization, Medical Therapy, and Anemia All Impact Patient Prognosis

TCT-111: Efficacy and Safety of Glycoprotein IIb/IIIa Inhibitors on Top of a Potent P2Y12 Inhibitor in STEMI: A Pre-Specified Sub-Analysis of the ATLANTIC Trial

Switching Between Oral P2Y12 Receptor Inhibitors: When and How?

Crushing and Chewing Oral P2Y12 Receptor Inhibitors: Pharmacodynamic and Clinical Impact

Debate: Making the Case for Not Pretreating ACS patients With Oral P2Y12 Receptor Inhibitors!

Debate: Making the Case for Pretreating ACS patients With Oral P2Y12 Receptor Inhibitors!

Treatment of Coronary Bifurcations in the Contemporary Era of P2Y12 Inhibitors and "Biologically Active Stents"

Help for Clinicians Whose Patients Need to Switch P2Y12 Inhibitors

Intravenous P2Y12 Receptor Inhibitors Transitioning to a Potent Oral Anti-platelet Agent if PCI Is Performed Is Optimal Treatment in NSTE-ACS

TCT 6: Simultaneous Impact of Thrombotic and Bleeding Risks on Use of Novel P2Y12 Inhibitors in Contemporary PCI: Results From a Large Single-Center Registry

Transitioning Between Cangrelor and Oral P2Y12 Inhibitors: All the Permutations

PAR-1 Antagonists and P2Y12 Inhibitors: What Are the Data and the Place of These Medications in the PAD Population (for Secondary Cardiovascular Prevention and PAD Itself)?

Experts Debate Optimal Pharmacologic Approach for STEMI Patients

Skeptic’s Corner: Experts Debate Aspirin Use in Patients with AF Receiving DES

Studies Find Differing Benefits of Platelet, Genotype Testing

EUROMAX: Prehospital Bivalirudin Reduces Bleeding in STEMI

Presentations Examine Multiple Facets of Antiplatelet Agents

P2Y12 Inhibitors: Specific Agents for Specific Patient Cohorts? (STEMI, Diabetes, CKD, Prior Stroke, Etc.)

P2Y12 Inhibitors: Could Platelet Reactivity to Balance Between Bleeding and Ischemic Events

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content